Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · Jan 23, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how different types of endometrial cancer (also known as uterine cancer) can affect treatment options for women who want to preserve their ability to have children. Many women with early-stage endometrial cancer can choose hormonal treatments instead of surgery, which can help them avoid losing their ability to get pregnant. The study aims to understand how different tumor classifications can predict which women are more likely to respond well to these fertility-sparing treatments.

To be eligible for this trial, women must be between 18 and 45 years old, have a confirmed diagnosis of early-stage endometrial cancer, and wish to preserve their fertility. The trial will use advanced tests to classify the cancer and ensure that there is no spread beyond the uterus. Participants will have regular check-ups to monitor their treatment progress. This study is important because it could help doctors provide more personalized care based on the specific characteristics of each patient's cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged 18-45 years with a hysteroscopic confirmed diagnosis of endometrial cancer (FIGO stage IA without myometrial invasion, grade 1 or grade 2, endometrioid histology).
• • 2. Patients desiring fertility preservation
• • 3. Molecular classification of the tumor using next-generation sequencing (NGS) or Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE).
• • 4. Adequate pre-treatment imaging (MRI or transvaginal ultrasound) confirming no evidence of myometrial invasion or extrauterine spread.
• Exclusion Criteria:
• • 1. Patients with atypical endometrial hyperplasia or intraepithelial neoplasia
• • 2. Individuals with tumor samples of insufficient quantity or inadequate quality were not included in the analysis
• • 3. Non-endometrioid histology.
• • 4. Patients with a history of prior uterine malignancy or current synchronous malignancies.
• • 5. Medical contraindications to hormonal therapy